Clinical outcomes and risk factors for immune recovery and all‐cause mortality in Latin Americans living with HIV with virological success: a retrospective cohort study
Open Access
- 17 March 2024
- journal article
- research article
- Published by Wiley in Journal of the International AIDS Society
- Vol. 27 (3) , e26214
Abstract
Introduction: Immune reconstitution following antiretroviral therapy (ART) initiation is crucial to prevent AIDS and non‐AIDS‐related comorbidities. Patients with suppressed viraemia who fail to restore cellular immunity are exposed to an increased risk of morbidity and mortality during long‐term follow‐up, although the underlying mechanisms remain poorly understood. We aim to describe clinical outcomes and factors associated with the worse immune recovery and all‐cause mortality in people living with HIV (PLWH) from Latin America following ART initiation.Methods: Retrospective cohort study using the CCASAnet database: PLWH ≥18 years of age at ART initiation using a three drug‐based combination therapy and with medical follow‐up for ≥24 months after ART initiation and undetectable viral load were included. Patients were divided into four immune recovery groups based on rounded quartiles of increase in CD4 T‐cell count at 2 years of treatment (350 cells/mm3). Primary outcomes included all‐cause mortality, AIDS‐defining events and non‐communicable diseases that occurred >2 years after ART initiation. Factors associated with an increase in CD4 T‐cell count at 2 years of treatment were evaluated using a cumulative probability model with a logit link.Results: In our cohort of 4496 Latin American PLWH, we found that patients with the lowest CD4 increase (<150) had the lowest survival probability at 10 years of follow‐up. Lower increase in CD4 count following therapy initiation (and remarkably not a lower baseline CD4 T‐cell count) and older age were risk factors for all‐cause mortality. We also found that older age, male sex and higher baseline CD4 T‐cell count were associated with lower CD4 count increase following therapy initiation.Conclusions: Our study shows that PLWH with lower increases in CD4 count have lower survival probabilities. CD4 increase during follow‐up might be a better predictor of mortality in undetectable PLWH than baseline CD4 count. Therefore, it should be included as a routine clinical variable to assess immune recovery and overall survival.Keywords
Funding Information
- Fondo de Financiamiento de Centros de Investigación en Áreas Prioritarias (ATE220016)
- Division of Microbiology and Infectious Diseases (U01AI069923)
This publication has 21 references indexed in Scilit:
- Discordant Immune Response with Antiretroviral Therapy in HIV-1: A Systematic Review of Clinical OutcomesPLOS ONE, 2016
- HIV infectionNature Reviews Disease Primers, 2015
- Initiation of Antiretroviral Therapy in Early Asymptomatic HIV InfectionNew England Journal of Medicine, 2015
- Monitoring of HIV treatment in seven countries in the WHO Region of the AmericasBulletin of the World Health Organization, 2015
- HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and MortalityPLOS Pathogens, 2014
- Enhanced CD4+ T-Cell Recovery with Earlier HIV-1 Antiretroviral TherapyNew England Journal of Medicine, 2013
- Incomplete Immune Recovery in HIV Infection: Mechanisms, Relevance for Clinical Care, and Possible SolutionsJournal of Immunology Research, 2012
- Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohortAIDS, 2012
- Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programmeInternational Journal of Epidemiology, 2007
- Lower CD4+ T Lymphocyte Nadirs May Indicate Limited Immune Reconstitution in HIV-1 Infected Individuals on Potent Antiretroviral Therapy: Analysis of Immunophenotypic Marker Results of AACTG 5067Journal of Clinical Immunology, 2005